FDA 483 - Dixon Investments Inc - March 22, 2019

Dixon Investments, Inc. DBA ARI, an OTC liquid and aerosol drug manufacturer in Orchard Hill, GA, was inspected by the FDA. The inspection revealed significant deficiencies in manufacturing process validation, quality control testing, discrepancy investigations, and stability testing. Several observations were repeat findings, indicating persistent issues with GMP compliance.